In the October 2016 issue of European Pharmaceutical Review, Andrew Butcher writes about the emergence of value-based pricing, where the price is determined as a function of measurable “value” brought by the product to relevant stakeholders. He discusses the challenges of measuring value in complex health systems and the importance of understanding the market and engaging a wide group of stakeholders well before a product launches. To read the article, click the link below.
Strategies for combination therapy in oncology: Part two – Working with the “status quo”
This is the second article in a three-part series examining the commercial dynamics surrounding combination therapy in oncology across the US and Europe. In...